原发纵隔大B细胞淋巴瘤诊断与治疗中国专家共识(2024年版)
Chinese expert consensus on the diagnosis and management of primary mediastinal large B-cell lymphoma(2024)
中华医学会血液学分会淋巴细胞疾病学组 中国临床肿瘤学会(CSCO)淋巴瘤专家委员会 徐兵 1赵维莅 2马军3
作者信息
- 1. 厦门大学附属第一医院,厦门大学血液病学系,厦门市血液病质控中心,厦门市血液治疗精准诊治重点实验室,厦门361003
- 2. 上海血液学研究所,医学基因组学国家重点实验室,转化医学国家重大科技基础设施(上海),上海交通大学医学院附属瑞金医院,上海200025
- 3. 哈尔滨血液病肿瘤研究所,哈尔滨 150010
- 折叠
摘要
原发纵隔大B细胞淋巴瘤(primary mediastinal large B-cell lymphoma,PMBL)是一种起源于纵隔的成熟侵袭性大B细胞淋巴瘤,具有独特的临床、病理及分子学特征.近年来,对PMBL发病机制的认识及治疗均有不同程度的更新,特别是新药治疗领域取得了较大进展.为提高我国临床医师对PMBL的诊断及治疗水平,中华医学会血液学分会淋巴细胞疾病学组和中国临床肿瘤学会(CSCO)淋巴瘤专家委员会组织相关专家组,制订了本共识.
Abstract
Primary mediastinal large B-cell lymphoma(PMBL)is an aggressive B-cell lymphoma that is thought to arise from thymic(medullary)B cells and has unique clinicopathologic and molecular fea-tures.In recent years,the understanding of the pathogenesis and treatment of PMBL has been updated to varying degrees,particularly in the area of new drug therapy.In order to improve the diagnosis and treat-ment of PMBL in China,the Lymphocyte Disease Group of the Chinese Medical Association(CMA)and the Anti-Lymphoma Alliance of the Chinese Society of Clinical Oncology(CSCO)commissioned a group of experts to formulate this consensus.
关键词
淋巴瘤,大B细胞/纵隔/诊断/治疗Key words
Lymphoma,Large B-Cell/Mediastinum/Diagnosis/Therapy引用本文复制引用
出版年
2024
NETL
NSTL
维普
万方数据